FiftyBidsGovernment contracts and grants, in one plain-English search.

Back to search

Forecast

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), as part of its stewardship of Congressionally-mandated activities under the Best Pharmaceuticals for Children Act (BPCA) and implementation of recommendations of the Task Force on Research Specific to Pregnant Women and…

FromNational Institutes of Health
Who can applystate governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types
Eligibility notesOther Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S.
How muchAmount not stated
DeadlineFri, Jul 9, 2027 (estimated) (258 days left)
CategoryHealth
TypeGrant
Opportunity #PAR-28-059
Assistance listing93.865
PostedThu, Aug 20, 2026

Heads-up: Forecast: not open yet. Dates and amounts are the agency's estimates.

Open the official posting

From the notice

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), as part of its stewardship of Congressionally-mandated activities under the Best Pharmaceuticals for Children Act (BPCA) and implementation of recommendations of the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC), intends to renew and publish a Notice of Funding Opportunity (NOFO) to solicit applications to promote translational and clinical research in pregnant women, lactating women, infants, children, and adolescents to: (1) advance precision medicine through the development, testing, and implementation of novel tools, models, and other technologies; (2) discover and develop novel therapeutics or enhance the usage of existing drugs for safer and more effective medications; (3) enhance patient-provider communications about drug effectiveness and safety risks; and, (4) optimize the dissemination, implementation, sustainment, and scale-up of evidence-based interventions to these patient populations. The overall goal is to improve safe and effective precision therapeutics during pregnancy, lactation, and across childhood. Applications are not being solicited at this time.

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.